Home

Health Care

BioBytes 104 - What is personalized medicine?

Personalized medicine will change the way patients are treated in the future - for the better. Learn more about personalized medicine - how it works, and why it could save consumers a lot of money.

BioBytes 101 - What is biotechnology?

This video provides a basic overview of biotechnology and its many applications in our daily lives.

BioBytes 103 - What are biotech drugs?

Are biotech drugs really that different from traditional pharmaceuticals.  You bet they are.  Learn why here.

BIO Media Briefing: Healthcare Reform Should Preserve Innovation

BIO President and CEO Jim Greenwood and BIO Board Chair Dr. Stephen Sherwin discuss the need to ensure that health care reform promotes and preserves innovation, particularly in a pathway for biosimilars and the use of comparative effectiveness data.

“The Ultimate Pig”
Jim Greenwood guest appearance on CNBC’s “Squawk Box” during this morning’s “Health Care Summit” special
Congressional Debate Continues on Data Exclusivity in Biosimilars Pathway
Patient groups join call for data protection
Victory on Biosimilars in Senate HELP Committee - But Still a Long Way from the Finish Line
The Washington Post: Special section on biotechnology
Health Reform Debate Heats Up and Slows Down

The health reform debate is heating up and, in at least one respect, slowing down a bit.

The Future of Healthcare: Personalized Medicine
Podcast: Bioinformatics Allows a Virtual Tour of the Human Body
Preparing Before the Storm: The Reimbursement Policy Disaster

During Tuesday's panel, we had the opportunity to lay the foundation of Medicare reimbursement policy, and discuss current trends and how health reform my impact reimbursement for biotechnology therapies in the future.

Developing Drugs for Rare Diseases

Letters, Testimony & Comments

BIO’s comments on the Centers for Medicare and Medicaid Services’ (CMS) draft 2014 Call Letter
March 1 2013
  BIO’s comments on the Centers for Medicare and Medicaid Services’ (CMS) draft 2014 Call Letter, submitted Friday,...
SMU: BIO Comments on Creating an Alternative Approval Pathway for Certain Drugs to Address Unmet Medical Need
March 1 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit...
Cell and Gene Therapy: BIO Comments on Preclinical Assessment of Investigational Cellular and Gene Therapy Products
February 27 2013
    Dear Sir/Madam:    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration...
Medicaid, Children’s Health Insurance Programs, and Exchanges
February 21 2013
Ms. Marilyn Tavenner, B.S.N., M.H.A. Acting Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H....
Electronic Submissions: BIO Comments on Providing Submissions in Electronic Format
February 19 2013
    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...
More Press Releases →